Loading clinical trials...
Loading clinical trials...
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
NCT04725240 · Hypothalamic Obesity
NCT06217848 · Panhypopituitarism, Craniopharyngioma, and more
NCT02664441 · Hypothalamic Obesity
NCT02860923 · Craniopharyngiomas, Hypothalamic Obesity
NCT00892073 · Hypothalamic Obesity
Children's Hospital Colorado
Aurora, Colorado
University of Iowa Children's Hospital
Iowa City, Iowa
Tufts Medical Center
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions